Calidi Biotherapeutics Stock Alpha and Beta Analysis
| CLDI Stock | 1.44 0.08 5.26% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Calidi Biotherapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Calidi Biotherapeutics over a specified time horizon. Remember, high Calidi Biotherapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Calidi Biotherapeutics' market risk premium analysis include:
Beta 2.45 | Alpha (2.32) | Risk 8.99 | Sharpe Ratio (0.26) | Expected Return (2.35) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Calidi Biotherapeutics Backtesting, Calidi Biotherapeutics Valuation, Calidi Biotherapeutics Correlation, Calidi Biotherapeutics Hype Analysis, Calidi Biotherapeutics Volatility, Calidi Biotherapeutics History and analyze Calidi Biotherapeutics Performance. Calidi Biotherapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Calidi Biotherapeutics market risk premium is the additional return an investor will receive from holding Calidi Biotherapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Calidi Biotherapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Calidi Biotherapeutics' performance over market.| α | -2.32 | β | 2.45 |
Calidi Biotherapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Calidi Biotherapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Calidi Biotherapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Calidi Biotherapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Calidi Biotherapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Calidi Biotherapeutics shares will generate the highest return on investment. By understating and applying Calidi Biotherapeutics stock market price indicators, traders can identify Calidi Biotherapeutics position entry and exit signals to maximize returns.
Calidi Biotherapeutics Return and Market Media
The median price of Calidi Biotherapeutics for the period between Fri, Jul 25, 2025 and Thu, Oct 23, 2025 is 1.65 with a coefficient of variation of 77.89. The daily time series for the period is distributed with a sample standard deviation of 2.45, arithmetic mean of 3.15, and mean deviation of 2.11. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Acquisition by Stewart Alan R. of 20217 shares of Calidi Biotherapeutics at 1.09 subject to Rule 16b-3 | 08/12/2025 |
2 | Insider Trading | 08/20/2025 |
3 | Acquisition by Andrew Jackson of 30000 shares of Calidi Biotherapeutics at 1.58 subject to Rule 16b-3 | 09/03/2025 |
4 | Can Calidi Biotherapeutics Inc. generate free cash flow - 2025 Biggest Moves Technical Entry and Exit Tips - khodrobank.com | 09/04/2025 |
5 | Calidi prices 1.47M units at 2.00 in underwritten public offering - MSN | 09/12/2025 |
6 | Calidi Biotherapeutics Streamlines Leadership with Role Elimination - TipRanks | 09/19/2025 |
7 | Atossa Therapeutics and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV - Fall River Herald News | 09/22/2025 |
8 | Calidi Biotherapeutics sinks after pricing 3.9M registered direct offering - MSN | 09/30/2025 |
9 | Atossa Therapeutics and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV - Iowa City Press-Citizen | 10/10/2025 |
10 | Is Calidi Biotherapeutics Inc. stock supported by strong cash flows - Quarterly Performance Summary Weekly Breakout Stock Alerts - newser.com | 10/14/2025 |
11 | Calidi Biotherapeutics Announces Establishment of Scientific Advisory Board to Support Development of CLD-401 and Advance its RedTail Platform for the Systemic ... | 10/22/2025 |
About Calidi Biotherapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Calidi or other stocks. Alpha measures the amount that position in Calidi Biotherapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2010 | 2024 | 2025 (projected) | Dividend Yield | 0.18 | 0.16 | 0.14 | Price To Sales Ratio | 625.63 | 1.7K | 1.0K |
Calidi Biotherapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Calidi Biotherapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Calidi Biotherapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Calidi Biotherapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Calidi Biotherapeutics. Please utilize our Beneish M Score to check the likelihood of Calidi Biotherapeutics' management manipulating its earnings.
| 13th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Calidi Biotherapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Calidi Biotherapeutics Backtesting, Calidi Biotherapeutics Valuation, Calidi Biotherapeutics Correlation, Calidi Biotherapeutics Hype Analysis, Calidi Biotherapeutics Volatility, Calidi Biotherapeutics History and analyze Calidi Biotherapeutics Performance. For more detail on how to invest in Calidi Stock please use our How to Invest in Calidi Biotherapeutics guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Calidi Biotherapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.